StockTwits Trending Alert: Trading recent interest in SERES THERAPEUTICS INC. COMMON STOCK $MCRB

The automated Quantcha Trade Ideas Service has detected a promising Long Risk Reversal trade opportunity for SERES THERAPEUTICS INC. COMMON STOCK (MCRB) for the 20-Oct-2017 expiration period. You can analyze the opportunity in depth over at the Quantcha Options Search Engine.

MCRB was recently trading at $12.72 and has an implied volatility of 112.36% for this period. Based on an analysis of the options available for MCRB expiring on 20-Oct-2017, there is a 34.60% likelihood that the underlying will close within the analyzed range of $12.71-$16.11 at expiration. In this scenario, the average linear return for the trade would be 15.82%.

Trending on StockTwits: StockTwits® is a financial communications platform for the financial and investing community. On their site, SERES THERAPEUTICS INC. COMMON STOCK was recently trending, indicating that breaking news and/or market activity has significantly impacted sentiment toward the stock. This movement can be interpretted as a sign of more near-term price movement for the underlying.

Trade approach: The recent sentiment change in MCRB on StockTwits appears to be significantly positive, indicating that the stock is likely to follow in that direction for investors trading on sentiment. As a result, a bullish strategy could prove effective if the sentiment ultimately turns out to drive trading.

Upside potential: Using this bullish strategy, the trade would be profitable if SERES THERAPEUTICS INC. COMMON STOCK closed at or above $12.10 on 20-Oct-2017. Based on our analysis, there is a 58.68% likelihood of this return.

Downside risk: As with any options trade, there is a substantial downside risk where you may lose most or all of your investment.

To analyze this trade in depth, please visit the Quantcha Options Search Engine.


This is an automated post generated based on a market analysis of delayed data at 10/2/2017 12:07:50 PM ET. The analysis does not include brokerage fees or commissions and is not investment advice.